I suggest you should spend about 30 minutes reading a couple of the Investor Presentations about the FSGS potential. Basically if Dimerix can successfully trial the pivotal phase 3, it will be 100’s millions per year exclusively during its orphan timeframe (7 or 10 years) depending the jurisdiction. Not a bad return for a 30+ million trial.
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-60
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $225.9M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 40.5¢ | 40.0¢ | $2.813K | 6.996K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4652 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 108685 | 6 |
View Market Depth
| Last trade - 10.22am 11/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |